Conclusions
EPICC, diabetes distress
SECONDARY
This secondary analysis of a randomized clinical trial identified improvement or worsening of at least 0.25 on the DDS-17 scale as the MCID. This MCID value is an appropriate method for assessing significant change in the DDS-17 from baseline to after a treatment intervention, given the evidence for an association between MCID improvements in DDS-17 scores among EPICC participants. The MCID values identified in this study can be used to inform future research examining diabetes distress using the DDS-17. Further, MCID values for DDS-17 can potentially be used by clinicians to assess response to treatments in their patients.